+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Neuroendocrine Carcinoma"

Neuroendocrine Tumors Drug Pipeline Analysis Report 2026 - Product Thumbnail Image

Neuroendocrine Tumors Drug Pipeline Analysis Report 2026

  • Drug Pipelines
  • May 2026
  • 150 Pages
  • Global
From
Carcinoid Tumor Drug Pipeline Analysis Report 2026 - Product Thumbnail Image

Carcinoid Tumor Drug Pipeline Analysis Report 2026

  • Drug Pipelines
  • May 2026
  • 150 Pages
  • Global
From
From
From
From
From
From
From
From
From
Radioligand Therapeutics in Cancer Treatment: Global Markets - Product Thumbnail Image

Radioligand Therapeutics in Cancer Treatment: Global Markets

  • Report
  • February 2026
  • 106 Pages
  • Global
From
From
From
From
Loading Indicator

Neuroendocrine carcinoma (NEC) is a rare type of cancer that affects the neuroendocrine system, which is responsible for the production of hormones. It is a type of cancer that is often difficult to diagnose and treat. Treatment options for NEC include surgery, chemotherapy, radiation therapy, and targeted therapies. Oncology drugs are used to treat NEC, and they can be used alone or in combination with other treatments. These drugs can help to reduce the size of tumors, slow the growth of cancer cells, and reduce the risk of recurrence. The Neuroendocrine Carcinoma market is a rapidly growing segment of the oncology drugs market. It is driven by the increasing prevalence of NEC, the development of new treatments, and the increasing availability of targeted therapies. Companies in the market include Novartis, Pfizer, Merck, AstraZeneca, and Roche. Show Less Read more